Back to Screener

Surrozen, Inc. Warrant (SRZNW)

Price$0.02

Favorite Metrics

Price vs S&P 500 (26W)-23.48%
Price vs S&P 500 (4W)8.41%

All Metrics

Price vs S&P 500 (YTD)-8.88%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.02M
52-Week High$1.21
26-Week Price Return-14.73%
13-Week Price Return8.52%
3-Month Return Std Dev326.99%
Year-to-Date Return-4.50%
5-Day Price Return9.14%
Month-to-Date Return19.38%
Price vs S&P 500 (13W)5.66%
Beta1.79x
52-Week Low$0.00

Industry Peers — Biological Products(89)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
SRZNWSurrozen, Inc. Warrant
$0.02
AMGNAmgen Inc
5.21x9.95%73.30%2.93%$355.30
GILDGilead Sciences Inc
5.80x2.40%78.83%133.64%$137.64
ARGXargenx SE American Depositary Shares
12.46x89.56%150.91%$849.04
BNTXBioNTech SE American Depositary Share
8.99x-11.81%84.21%$102.92
BIIBBiogen Inc. Common Stock
2.63x2.22%75.69%-18.77%$177.35
MRNAModerna, Inc. Common Stock
10.91x-39.93%70.32%$53.72
NBIXNeurocrine Biosciences Inc
4.68x21.45%98.18%2.31%$133.25
EXELExelixis Inc
5.02x6.85%96.39%31.10%$44.89
TECHBio-Techne Corp.
7.62x1.64%66.60%-20.58%$59.23
HALOHalozyme Therapeutics, Inc.
5.88x37.55%83.62%22.89%$69.29

About

Surrozen Inc is a clinical-stage biotechnology company developing therapies that modulate the Wnt pathway to promote tissue repair across multiple organ systems. The company is advancing a pipeline of drug candidates, including SZN-1326, SZN-413, and SZN-043, each targeting distinct mechanisms to maximize therapeutic potential. Surrozen's focused approach to Wnt pathway biology aims to address unmet clinical needs in regenerative medicine and tissue homeostasis.